Articles tagged "Hepatocellular carcinoma"

2022 American Transplant Congress
Induction Immunosuppression Does Not Worsen Tumor Recurrence After Liver Transplantation for T2 Hepatocellular Carcinoma and May Allow for Decreased Mortality
C. Durkin¹, T. Bittermann¹, D. E. Schaubel²
¹Gastroenterology, University of Pennsylvania, Philadelphia, PA, ²Biostatistics, University of Pennsylvania, Philadelphia, PA
*Purpose: Prior studies have suggested that induction therapy leads to worse outcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC). This study evaluated the impact…
2022 American Transplant Congress
A Intention-to-Treat Analysis of 881 Consecutively Waitlisted Patients to Develop a Survival Benefit Model for Hepatocellular Carcinoma Liver Transplant Candidates
B. V. Tran¹, W. Lapisatepun¹, W. Dumronggittigule¹, D. Markovic², Y. Lee¹, F. Kaldas¹, D. Farmer¹, R. Busuttil¹, V. Agopian¹
¹Department of Surgery, University of California Los Angeles, Los Angeles, CA, ²Department of Medicine, Statistics Core, University of California Los Angeles, Los Angeles, CA
*Purpose: The current liver transplantation (LT) selection paradigm for hepatocellular carcinoma (HCC) patients ignores the variable risks of waitlist dropout and post-LT recurrence/death, with the…
2022 American Transplant Congress
Increased Regulatory T-cells in Tumor Microenvironment is Associated with Hepatocellular Carcinoma Differentiation in Patients Undergoing Liver Transplantation
G. Orozco¹, R. Gedaly², L. Turcios², F. Marti²
¹Surgery, University of Kentucky, Lexington, KY, ²UKHC, Lexington, KY
*Purpose: Tumor-infiltrating lymphocytes are an essential component of the tumor microenvironment. The balance between cytotoxic effector T cells and immunosuppressive regulatory T cells is critical…
2022 American Transplant Congress
Immune Checkpoints, Immune Cells, and MHC Expression in the Tumor Microenvironment of Resected Hepatocellular Carcinomas
A. Baquerizo¹, V. Vavinskaya², S. Bagsic¹, A. Rojas³, A. Mhoyan⁴, C. Frenette¹, L. Sher⁵, M. Romero³, J. Fisher¹, C. Marsch¹, R. Schaffer¹
¹Scripps, La Jolla, CA, ²UCSD, San Diego, CA, ³University, Seville, Spain, ⁴Kaiser, San Diego, CA, ⁵USC, Los Angeles, CA
*Purpose: Advances in tumor biology has shown the important role of the tumor microenvironment (TME) in tumor growth and metastasis. A better understanding of the…
2022 American Transplant Congress
Disparities in Liver Transplantation in Patients with HCC Diagnosis
C. Warren¹, A. Zarrinpar²
¹Surgery, University of Florida Shands Health, Gainesville, FL, ²Surgery, University of Florida Health Shands, Gainesville, FL
*Purpose: Disparities in outcomes of hepatocellular carcinoma (HCC) have not been adequately studied, especially in the context of liver transplantation (LT). We sought to identify…
2022 American Transplant Congress
Liver Transplantation for Patients with Fibrolamellar Hepatocellular Carcinoma: A Comprehensive Multicenter Analysis to Support Future Decision Making
M. P. Claasen¹, T. Ivanics¹, W. G. Polak², J. N. IJzermans², G. Sapisochin¹
¹Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ²HPB and Transplant Surgery, Erasmus MC, Rotterdam, Netherlands
*Purpose: Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare tumour accounting for ~1% of all primary liver cancers. Due to its rarity, there is a shortage…
2022 American Transplant Congress
Differentially Methylated Genes Predict Post-Transplant Relapse of Unresectable Hepatoblastoma
M. Ningappa¹, M. Muarya², C. Ashokkumar¹, H. Hakonarson³, S. Subramaniam⁴, R. Sindhi¹
¹Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Department of Bioengineering & San Diego Supercomputer Center, University of California, San Diego, CA, ³Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Department of Computer Science and Engineering, and Nanoengineering, University of California, San Diego, La Jolla, CA
*Purpose: Hepatoblastoma (HB), a developmental liver tumor of childhood requires liver transplantation (LT) if it remains unresectable despite chemotherapy. Post-transplant relapse in up to 20%…
2022 American Transplant Congress
The Oncological Influences of Pre- and Post-Transplant Sustained Viral Response in Liver Transplant for Hepatocellular Carcinoma
K. Sasaki¹, S. Kimura², K. Tomiyama³, Y. Bekki⁴, M. Murray³, P. Huang³, M. Fruscione², A. Moro⁵, C. Kwon⁶
¹Stanford University, Stanford, CA, ²Massachusetts General Hospital, Boston, MA, ³University of Rochester, Rochester, NY, ⁴Mount Sinai Medical Center, New York, NY, ⁵University of South Florida, Tampa, FL, ⁶Cleveland Clinic, Cleveland, OH
*Purpose: Chronic hepatitis C infection (HCV) is one of the most common causes of hepatocellular carcinoma. After emerging direct-acting agents (DAA), the success rate of…
2022 American Transplant Congress
Role of Circulating Tumour Cells in the Management of the Liver Transplant Patient with Hepatocellular Carcinoma
F. Villalba¹, F. Alconchel², L. Sáenz³, M. Sánchez-Lorencio¹, D. Ferreras², P. Cascales², F. Sánchez-Bueno², R. Robles², P. Ramírez²
¹IMIB-Virgen de la Arrixaca, Murcia, Spain, ²Surgery and Organ Transplantation, Virgen de la Arrixaca University Hospital (IMIB-Virgen de la Arrixaca), Murcia, Spain, ³Rafael Méndez Hospital, Lorca, Spain
*Purpose: For hepatocellular carcinoma (HCC), liver transplantation (LT) is considered a curative treatment, however, more than 10% of transplant recipients have recurrences within the first…
2022 American Transplant Congress
Higher Hepatocellular Carcinoma Tumor Burden Score is Associated with Grater Liver Transplant Survival Benefit
H. Liu¹, W. Zhang², M. Di³, H. Lee⁴, R. Cruz¹, X. Wang², C. Kaltenmeier¹, A. Thompson¹, D. Reddy¹, E. Ashwat¹, M. D'Alesio¹, S. Lebowitz¹, S. Tohme¹, D. Geller¹, A. Tevar¹, C. Hughes¹, A. Humar¹, J. Behari⁵, R. Bataller⁵, S. Hariharan⁵, M. Molinari¹
¹Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Mathematics and Statistics, University of Arkansas at Little Rock, Little Rock, AR, ³Medicine, Medical Oncology, Yale University, New Haven, CT, ⁴Biostatistics, Massachusetts General Hospital, Boston, MA, ⁵Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Liver transplantation(LT) is the best treatment option for early-stage hepatocellular carcinoma(HCC) and cirrhosis. However, patients with various tumor burdens receive identical listing priority, despite…

1
2
3
…
23
Next Page »